ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Biologics in severe asthma: the role of real-world evidence from registries.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- The Hidden Risk of Toxoplasmosis in the Expanding Immunomodulated Host Population: A Call for Guidelines and Registries in Patients on Biologics, Small Molecules, and Cellular Therapies.Pathogens (Basel, Switzerland) · 2026Article
- Investigation of Biomarkers in Allergic Patients with Long COVID.Journal of personalized medicine · 2026Article
- Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study.The journal of allergy and clinical immunology. Global · 2026Article
- Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2025Article
- International Severe Asthma Registry (ISAR): 2017-2024 Status and Progress Update.Tuberculosis and respiratory diseases · 2025Article
- Expert Perspectives on Next Generation Health Guidelines: How to Integrate RWE in EBM.Pragmatic and observational research · 2025Article
- Case Report: Extending dosing intervals of biologics in adults severe asthma: a case series.Frontiers in allergy · 2025Article
- Real-World Experience of Dupilumab Treatment for Patients with COPD - A Single Center Prospective Study.International journal of chronic obstructive pulmonary disease · 2025Observational
- Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI).The World Allergy Organization journal · 2025Article
- Real-World and Patient-Reported Outcomes of Dupilumab and Other Biological Drugs for Chronic Obstructive Pulmonary Disease-A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.Journal of personalized medicine · 2024Article
- Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR.Allergy, asthma & immunology research · 2024Article
- Severe asthma care trajectories: the French RAMSES cohort.ERJ open research · 2024Article
- Parasitic Infections and Biological Therapies Targeting Type 2 Inflammation: A VigiBase Study.American journal of respiratory and critical care medicine · 2023Article
- Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis.ERJ open research · 2023Article
- Real-world data: A relevant component in the framework of scientific evidence.Asia Pacific allergy · 2023Review
- Roles of real-world evidence in severe asthma treatment: challenges and opportunities.ERJ open research · 2023Article
- Adult Severe Asthma Registries: A Global and Growing Inventory.Pragmatic and observational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is one of the most common noncommunicable diseases; in the majority of patients it is well controlled with inhaled bronchodilators and inhaled corticosteroids, but the management of severe asthma has been a significant challenge historically. The introduction of novel biologic drugs in the past few decades has revolutionised the field, presenting physicians with a variety of biologic drugs with different mechanisms for the treatment of severe asthma.It is of crucial importance to evaluate the effectiveness of these drugs by following their "real-life" effectiveness rather than relying solely on their efficacy, established in carefully designed clinical trials, which therefore do not necessarily match the profile of the real-life patient. Understanding the actual effectiveness of the specific drugs in real-life patients is a crucial part of tailoring the right drugs to the right patients. Registries serve as an important tool in obtaining real-life evidence, since they are in effect observational studies, following the entire patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.